Skip to main navigation
Tenaya Therapeutics
  • Careers at Tenaya
  • Contact Us
  • Leadership
  • Our Science
    • Platforms
    • Capabilities
    • Collaborations
    • Publications & Presentations
  • Our Programs
    • Pipeline
    • Programs
  • Patients
    • Elevating Patient Voices
    • Advocacy at Tenaya
    • Clinical Studies
    • Gene Therapy for Cardiomyopathies
    • Advocacy Partners
  • Investors
    • News & Events
      • Press Releases
      • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • IR Resources
      • Investor FAQs
      • Contact IR
      • Email Alerts
  • HCP Resource Center
    • Genetic Medicine Primer
      • About Gene Therapy
    • TN-201 for MYBPC3– associated HCM
      • Hypertrophic Cardiomyopathy and Genetics
      • How TN-201 Works
      • MyPEAK-1 Phase 1b/2 Clinical Trial
      • Tenaya’s Non-interventional Studies for MYBPC3 HCM
      • Webinars
      • FAQ’s
    • TN-401 for PKP2– associated ARVC
      • ARVC and Genetics
      • How TN-401 works
      • RIDGE-1 Phase 1b Clinical Trial
      • Tenaya’s Non-interventional Study for PKP2-Associated ARVC
      • FAQ’s

Investor Portal

Document Details

Form
SCHEDULE 13D/A
Filing Date
Dec 17, 2025
Document Date
Dec 17, 2025
Form Description
SCHEDULE 13D/A - Description
Filing Group
Other
Company
Tenaya Therapeutics, Inc.
Issuer
TENAYA THERAPEUTICS, INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
RSS Feeds
Email Alerts
Contact IR
Print

Privacy Policy | Cookie Policy | Terms of Use | Community Guidelines
© 2026 Tenaya Therapeutics. All rights reserved.